CDKN1C
CDKN1C (cyclin dependent kinase inhibitor 1C, also known as P57, KIP2, BWCR and BWS) is a nuclear protein that binds and inhibits G1 cyclin/CDK complexes. It acts as a negative regulator of cell proliferation and is a tumour suppressor candidate. Browse Assay Genie's current range of CDKN1C research reagents below, or read on for the biology behind the target.
CDKN1C is a potent, tight-binding inhibitor of several G1 cyclin/CDK complexes, including cyclin E-CDK2, cyclin D2-CDK4 and cyclin A-CDK2. It inhibits the mitotic cyclin B-CDC2 complex to a lesser extent. By restraining these kinase complexes it acts as a negative regulator of cell proliferation, and it may help maintain the non-proliferative state throughout life.
The CDKN1C protein is localised to the nucleus and belongs to the CDI family. HGNC places the CDKN1C gene in the cyclin dependent kinase inhibitor 1 family, alongside CDKN1A and CDKN1B. The gene is imprinted, with preferential expression of the maternal allele. Three transcript variants encoding two different isoforms have been reported. The mouse ortholog is Cdkn1c.
The protein is also known as p57 or Kip2, and the previous HGNC name was cyclin-dependent kinase inhibitor 1C (p57, Kip2). The aliases BWCR and BWS, and the earlier name Beckwith-Wiedemann syndrome, reflect a disease link. Mutations in this gene are implicated in sporadic cancers and in Beckwith-Wiedemann syndrome, which is why CDKN1C is regarded as a tumour suppressor candidate. Researchers studying cell cycle control, genomic imprinting and growth disorders use CDKN1C as a reference point, whether they work with a CDKN1C antibody, a CDKN1C ELISA kit or recombinant CDKN1C protein.
CDKN1C inhibits cyclin E-CDK2, cyclin D2-CDK4 and cyclin A-CDK2, making it a key subject for studying the G1 phase.
Mutations in CDKN1C are implicated in sporadic cancers, so it is studied as a tumour suppressor candidate.
CDKN1C is imprinted with preferential maternal allele expression, providing a model for parent-of-origin gene regulation.
Mutations in this gene are implicated in Beckwith-Wiedemann syndrome, linking CDKN1C to the study of this overgrowth disorder.
CDKN1C is a potent, tight-binding inhibitor of several G1 cyclin/CDK complexes, including cyclin E-CDK2, cyclin D2-CDK4 and cyclin A-CDK2, and to a lesser extent cyclin B-CDC2. It negatively regulates cell proliferation and may help maintain the non-proliferative state throughout life.
CDKN1C is also called P57 or KIP2, with BWCR and BWS as further aliases. Earlier HGNC names were Beckwith-Wiedemann syndrome and cyclin-dependent kinase inhibitor 1C (p57, Kip2). Three transcript variants encoding two different isoforms have been reported for the gene.
Mutations in CDKN1C are implicated in sporadic cancers and Beckwith-Wiedemann syndrome, so it is considered a tumour suppressor candidate. The mouse ortholog is Cdkn1c. Check the datasheet of any product for its validated reactivity.
Other cyclin dependent kinase inhibitors and cell cycle regulators with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P49918; product specifications from Assay Genie datasheets.